APTO
Price:
$0.379
Market Cap:
$6.86M
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic...[Read more]
Industry
Biotechnology
IPO Date
1992-03-16
Stock Exchange
NASDAQ
Ticker
APTO
According to Aptose Biosciences Inc.’s latest financial reports and current stock price. The company's current ROE is -5693.38%. This represents a change of 255.80% compared to the average of -1600.16% of the last 4 quarters.
The mean historical ROE of Aptose Biosciences Inc. over the last ten years is 95.06%. The current -5693.38% ROE has changed -6088.99% with respect to the historical average. Over the past ten years (40 quarters), APTO's ROE was at its highest in in the December 2023 quarter at 425.67%. The ROE was at its lowest in in the March 2024 quarter at -7012.33%.
Average
95.06%
Median
-82.66%
Minimum
-205.01%
Maximum
1.81%
Discovering the peaks and valleys of Aptose Biosciences Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 170.00%
Maximum Annual ROE = 1.81%
Minimum Annual Increase = -1761.00%
Minimum Annual ROE = -205.01%
Year | ROE | Change |
---|---|---|
2023 | 1.81% | -1761.00% |
2022 | -108.78% | 23.73% |
2021 | -87.91% | 91.08% |
2020 | -46.01% | 68.16% |
2019 | -27.36% | -86.66% |
2018 | -205.01% | 79.36% |
2017 | -114.30% | -39.62% |
2016 | -189.30% | 144.52% |
2015 | -77.41% | 170.00% |
2014 | -0.05% | -99.88% |
The current ROE of Aptose Biosciences Inc. (APTO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
536.69%
5-year avg
307.34%
10-year avg
95.06%
Aptose Biosciences Inc.’s ROE is less than CytomX Therapeutics, Inc. (-27.44%), less than Instil Bio, Inc. (-55.57%), less than Neoleukin Therapeutics, Inc. (-47.64%), less than Spero Therapeutics, Inc. (20.70%), greater than Assembly Biosciences, Inc. (-121.55%), greater than Fortress Biotech, Inc. (-226.63%), less than Mustang Bio, Inc. (1.40%), less than Achilles Therapeutics plc (-47.36%), greater than Fortress Biotech, Inc. (-226.63%), greater than Gain Therapeutics, Inc. (-214.20%), greater than TFF Pharmaceuticals, Inc. (-225.16%), less than aTyr Pharma, Inc. (-56.83%), greater than IN8bio, Inc. (-173.12%), less than Lantern Pharma Inc. (-46.39%), greater than Affimed N.V. (-155.57%), greater than Leap Therapeutics, Inc. (-98.01%), greater than Adaptimmune Therapeutics plc (-117.47%), less than Corvus Pharmaceuticals, Inc. (-53.99%), less than Longboard Pharmaceuticals, Inc. (-36.93%), greater than TRACON Pharmaceuticals, Inc. (-237.65%), less than Oncternal Therapeutics, Inc. (120.03%), less than Aeglea BioTherapeutics, Inc. (197.28%),
Company | ROE | Market cap |
---|---|---|
-27.44% | $95.30M | |
-55.57% | $427.15M | |
-47.64% | $8.20M | |
20.70% | $72.97M | |
-121.55% | $113.14M | |
-226.63% | $44.94M | |
1.40% | $9.48M | |
-47.36% | $28.99M | |
-226.63% | $45.96M | |
-214.20% | $37.54M | |
-225.16% | $7.87M | |
-56.83% | $131.12M | |
-173.12% | $14.45M | |
-46.39% | $40.69M | |
-155.57% | $60.22M | |
-98.01% | $114.79M | |
-117.47% | $279.81M | |
-53.99% | $370.93M | |
-36.93% | $1.19B | |
-237.65% | $204.45K | |
120.03% | $4.29M | |
197.28% | $48.63M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aptose Biosciences Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aptose Biosciences Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Aptose Biosciences Inc.'s ROE?
How is the ROE calculated for Aptose Biosciences Inc. (APTO)?
What is the highest ROE for Aptose Biosciences Inc. (APTO)?
What is the 3-year average ROE for Aptose Biosciences Inc. (APTO)?
What is the 5-year average ROE for Aptose Biosciences Inc. (APTO)?
How does the current ROE for Aptose Biosciences Inc. (APTO) compare to its historical average?